{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:20:35Z","timestamp":1794558035683,"version":"4.9.1"},"reference-count":36,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2010,10,6]],"date-time":"2010-10-06T00:00:00Z","timestamp":1286323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2011,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Therapies for psoriasis have focused not only on ameliorating the severity of the skin lesions, but also on the quality of life (QOL). Here, the efficacy of low\u2010dose, short\u2010term administration of ciclosporin (Neoral<jats:sup>\u00ae<\/jats:sup>, as CyA) was investigated. Forty\u2010one psoriasis patients were given CyA orally (3\u2003mg\/kg per day) twice daily before breakfast and dinner until the psoriatic area and severity index (PASI) scores decreased by at least 75%. Surveys were conducted before and after the therapy to ascertain QOL, itch, nail condition, joint pain, stress associated with topical application and therapy satisfaction. QOL was assessed by using the Japanese version of Skindex\u201016 specific to skin diseases, and the Japanese version of the GHQ\u201028, which assesses mental health. Data collected from 35 patients were analyzed. Remission was achieved in 26 patients (74%), and the average length required to achieve remission was 101.5\u2003days. The average PASI score significantly decreased from 17.8 to 3.3 after the therapy. Remission lasted 6\u2003months or longer in 40% of the patients. The average length of time before restarting systemic therapy was 182.0\u2003days. This duration for patients with PASI scores of &lt;13 was 287.5\u2003days while for patients with PASI scores of \u226513, it was significantly shorter at 120.1\u2003days. Five adverse events were recorded in three patients, but were not serious. The total Skindex\u201016 score significantly decreased especially in the \u201cemotions\u2019 and \u201cfunctioning\u201d categories. GHQ scores also significantly decreased in \u201csomatic symptoms,\u201d\u201canxiety and insomnia,\u201d and \u201cdepression\u201d. With regard to patients\u2019 satisfaction with their therapy, 88.5% of the patients reported \u201csatisfied\u201d or \u201cslightly satisfied\u201d. These results demonstrate that low\u2010dose, short\u2010term administration of CyA (3\u2003mg\/kg per day) is one of the best therapies for psoriasis patients with PASI scores of &lt;13, while QOL assessment is a very useful tool for evaluating the value of therapy.<\/jats:p>","DOI":"10.1111\/j.1346-8138.2010.01041.x","type":"journal-article","created":{"date-parts":[[2010,10,6]],"date-time":"2010-10-06T04:36:34Z","timestamp":1286339794000},"page":"465-472","source":"Crossref","is-referenced-by-count":21,"title":["Low\u2010dose, short\u2010term ciclosporin (Neoral<sup>\u00ae<\/sup>) therapy is effective in improving patients\u2019 quality of life as assessed by Skindex\u201016 and GHQ\u201028 in mild to severe psoriasis patients"],"prefix":"10.1111","volume":"38","author":[{"given":"Yukari","family":"OKUBO","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"NATSUME","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kae","family":"USUI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misato","family":"AMAYA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"TSUBOI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,10,6]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1987.tb01844.x"},{"key":"e_1_2_5_3_2","first-page":"210","article-title":"Dermatology life quality index (DLQI) \u2013 a simple practical measure for routine clinical use","volume":"19","author":"Finlay AY","year":"1994","journal-title":"Br J Dermatol"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70112-X"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.106374"},{"key":"e_1_2_5_6_2","first-page":"2059","article-title":"The results of a satisfaction survey concerning treatment for psoriasis patients","volume":"113","author":"Nemoto O","year":"2003","journal-title":"Jpn J Dermatol"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0022-202X.2003.09101.x"},{"key":"e_1_2_5_8_2","first-page":"863","article-title":"Clinical importance of evaluation of quality of life in patients with psoriasis: treatment from the patients\u2019 point of view","volume":"115","author":"Nakagawa H","year":"2005","journal-title":"Jpn J Dermatol"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06909.x"},{"key":"e_1_2_5_10_2","first-page":"2495","article-title":"Assessment of the quality of life of patients with psoriasis using Skindex\u201016 and GHQ\u201028","volume":"117","author":"Okubo Y","year":"2007","journal-title":"Jpn J Dermatol"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(03)01870-X"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0366-077X.2004.05949.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02556.x"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630701646156"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08337.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.8.5.617"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2007.02534.x"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199101313240501"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.112400"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0366-077X.2004.05950.x"},{"key":"e_1_2_5_21_2","first-page":"116","article-title":"Methotrexate vs.ciclosporin in psoriasis","volume":"158","author":"Flystr\u00f6m I","year":"2008","journal-title":"Br J Dermatol"},{"key":"e_1_2_5_22_2","first-page":"1093","article-title":"A consensus conference report on psoriasis therapy with cyclosporine MEPC","volume":"114","author":"Nakagawa H","year":"2004","journal-title":"Jpn J Dermatol"},{"key":"e_1_2_5_23_2","first-page":"280","article-title":"The impact of psoriasis on quality of life","volume":"137","author":"Krueger G","year":"2008","journal-title":"Arch Dermatol"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:QURE.0000015293.69661.ff"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04183.x"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1997.d01-1229.x"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2003.tb00390.x"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2002.tb00205.x"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12365600"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1997.03890470111018"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02737863"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5707.439"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.5.508"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291700021644"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291700050972"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06502.x"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2007.00305.x"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1346-8138.2010.01041.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1346-8138.2010.01041.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T21:50:53Z","timestamp":1697320253000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1346-8138.2010.01041.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,6]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["10.1111\/j.1346-8138.2010.01041.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1346-8138.2010.01041.x","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,6]]}}}